These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
951 related articles for article (PubMed ID: 33574119)
21. Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study. Plebani M; Parčina M; Bechri I; Zehender G; Terkeš V; Abdel Hafith B; Antinori S; Pillet S; Gonzalo S; Hoerauf A; Lai A; Morović M; Bourlet T; Torre A; Pozzetto B; Galli M J Clin Microbiol; 2021 Jan; 59(2):. PubMed ID: 33218990 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of 18 commercial serological assays for the detection of antibodies against SARS-CoV-2 in paired serum samples. Hanssen DAT; Slaats M; Mulder M; Savelkoul PHM; van Loo IHM Eur J Clin Microbiol Infect Dis; 2021 Aug; 40(8):1695-1703. PubMed ID: 33733395 [TBL] [Abstract][Full Text] [Related]
23. Performance characteristics of five SARS-CoV-2 serological assays: Clinical utility in health-care workers. Heffernan E; Kennedy L; Hannan MM; Ramlaul N; Denieffe S; Courtney G; Watt A; Hurley J; Lynch M; Fitzgibbon M Ann Clin Biochem; 2021 Sep; 58(5):496-504. PubMed ID: 33845592 [TBL] [Abstract][Full Text] [Related]
24. The role and diagnostic accuracy of serology for COVID-19. Kundu D; Gautam P; Dayanand D; Gunasekaran K; Manesh A; Sebastian M; Abhilash KPP; Zachariah A; George T; Sathyendra S; Hansdak SG; Abraham OC; Iyadurai R; Thangakunam B; Gupta R; Karthik R; Moorthy M; Varghese GM BMC Infect Dis; 2022 Apr; 22(1):390. PubMed ID: 35439957 [TBL] [Abstract][Full Text] [Related]
25. Increasing the Efficiency of a National Laboratory Response to COVID-19: a Nationwide Multicenter Evaluation of 47 Commercial SARS-CoV-2 Immunoassays by 41 Laboratories. van den Beld MJC; Murk JL; Kluytmans J; Koopmans MPG; Reimerink J; van Loo IHM; Wegdam-Blans MCA; Zaaijer H; ; GeurtsvanKessel C; Reusken C J Clin Microbiol; 2021 Aug; 59(9):e0076721. PubMed ID: 34191578 [TBL] [Abstract][Full Text] [Related]
26. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Van Elslande J; Decru B; Jonckheere S; Van Wijngaerden E; Houben E; Vandecandelaere P; Indevuyst C; Depypere M; Desmet S; André E; Van Ranst M; Lagrou K; Vermeersch P Clin Microbiol Infect; 2020 Nov; 26(11):1557.e1-1557.e7. PubMed ID: 32745595 [TBL] [Abstract][Full Text] [Related]
27. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485 [TBL] [Abstract][Full Text] [Related]
28. Validation and performance comparison of three SARS-CoV-2 antibody assays. Paiva KJ; Grisson RD; Chan PA; Huard RC; Caliendo AM; Lonks JR; King E; Tang EW; Pytel-Parenteau DL; Nam GH; Yakirevich E; Lu S J Med Virol; 2021 Feb; 93(2):916-923. PubMed ID: 32710669 [TBL] [Abstract][Full Text] [Related]
29. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Bond KA; Williams E; Nicholson S; Lim S; Johnson D; Cox B; Putland M; Gardiner E; Tippett E; Graham M; Mordant F; Catton M; Lewin SR; Subbarao K; Howden BP; Williamson DA Pathology; 2021 Oct; 53(6):773-779. PubMed ID: 34412859 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays. Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714 [TBL] [Abstract][Full Text] [Related]
31. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay. Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Tancevski I; Weiss G; Anliker M; Griesmacher A; Hoermann G Clin Chem Lab Med; 2021 May; 59(6):1143-1154. PubMed ID: 33554557 [TBL] [Abstract][Full Text] [Related]
33. The reliability of SARS-CoV-2 IgG antibody testing - a pilot study in asymptomatic health care workers in a Croatian university hospital. Lapić I; Rogić D; Šegulja D; Kralik Oguić S; Knežević J Croat Med J; 2020 Dec; 61(6):485-490. PubMed ID: 33410294 [TBL] [Abstract][Full Text] [Related]
34. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2. Theel ES; Harring J; Hilgart H; Granger D J Clin Microbiol; 2020 Jul; 58(8):. PubMed ID: 32513859 [TBL] [Abstract][Full Text] [Related]
35. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). Nicol T; Lefeuvre C; Serri O; Pivert A; Joubaud F; Dubée V; Kouatchet A; Ducancelle A; Lunel-Fabiani F; Le Guillou-Guillemette H J Clin Virol; 2020 Aug; 129():104511. PubMed ID: 32593133 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays. Tanis J; Vancutsem E; Piérard D; Weets I; Bjerke M; Schiettecatte J; De Geyter D Diagn Microbiol Infect Dis; 2021 May; 100(1):115313. PubMed ID: 33548855 [TBL] [Abstract][Full Text] [Related]
37. Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys® anti-SARS-CoV-2 immunoassay. Kittel M; Findeisen P; Muth MC; Thiaucourt M; Gerhards C; Neumaier M; Haselmann V Int J Infect Dis; 2021 Apr; 105():632-638. PubMed ID: 33578017 [TBL] [Abstract][Full Text] [Related]
38. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population. Ige F; Hamada Y; Steinhardt L; Iriemenam NC; Uwandu M; Greby SM; Aniedobe M; Salako BL; Rangaka MX; Abubakar I; Audu R Microbiol Spectr; 2021 Oct; 9(2):e0068021. PubMed ID: 34612691 [TBL] [Abstract][Full Text] [Related]
39. Usefulness of ELISA Using Total Antibody against Plant-Expressed Recombinant Nucleocapsid Protein of SARS-CoV-2. Tariq M; Hur J; Seo JW; Kim DY; Yun NR; Lee YM; Bang MS; Hwang SY; Kim CM; Lee JH; Song KH; Lee H; Jung J; Park JY; Kim HB; Kim ES; Lee S; Kim DM Microbiol Spectr; 2021 Dec; 9(3):e0067221. PubMed ID: 34817278 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of ten (10) SARS-CoV-2 rapid serological tests in comparison with WANTAI SARS-CoV-2 ab ELISA in Burkina Faso, West Africa. Ouedraogo HG; Zoure AA; Compaoré TR; Ky H; Zida S; Zingué D; Ouedraogo O; Soubeiga ST; Sagna T; Dabiré C; Kambiré D; Zongo D; Yonli AT; Nikiema AR; Nezien D; Bansé GC; Bicaba BW; Perier S; Sawadogo C; Yabre Z; Sangare L Virol J; 2023 Mar; 20(1):57. PubMed ID: 36997951 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]